key: cord-1051064-s0djf8hz authors: El-Lababidi, Rania M.; Mooty, Mohamad; Bonilla, Maria-Fernanda; Salem, Nouran M. title: Treatment of Severe Pneumonia due to COVID-19 with Peginterferon alfa 2a date: 2020-05-22 journal: IDCases DOI: 10.1016/j.idcr.2020.e00837 sha: 66bc40bd3ea9bec129922138a2df0bf22d8b652a doc_id: 1051064 cord_uid: s0djf8hz The outbreak of the new coronavirus disease 2019 (COVID-19) has spread rapidly worldwide. Until now, no definite effective treatment has been identified. We reported 3 patients with severe COVID-19 treated with pegylated interferon alfa 2a with satisfactory recovery. Based on these observations, randomized studies with interferons should be considered in deteriorating patients infected with COVID-19. The outbreak of pneumonia due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) originating in Wuhan, China has rapidly spread to become a pandemic as assessed by the World Health Organization. As of April 19, 2020 , the total number of confirmed cases has reached 2,241,359 cases, with a total of 152,552 deaths worldwide [1] . There is an urgent need to develop an effective regimen for COVID-19, given the high infectivity of this novel virus and the rapid progression of this disease. The majority of patients with SARS-CoV-2 seem to have a non-complicated course, with an asymptomatic or mild presentation. However, the disease may progress rapidly to severe pneumonia and acute respiratory distress syndrome (ARDS), requiring mechanical ventilation in a considerable number of patients [2] . Patients with a severe presentation of COVID-19 often present with lymphopenia, leukopenia and elevated inflammatory markers, demonstrating a significant immune response [2, 3] . There is some evidence that severe deterioration, leading to ARDS is driven by a cytokine storm and that early intervention and suppression of this cytokine dysregulation may play a role in preventing the severe stages of the disease [4] . Here we report on 3 patients with COVID-19 who received peginterferon alfa 2a at the time they developed respiratory distress, with satisfactory clinical and radiographic recovery. On March 1, 2020 a 38-year-old male who was otherwise healthy was admitted to our institution with a history of high-risk exposure to SARS-CoV-2. He had no symptoms of COVID-19 and was doing well. He arrived in the United Arab Emirates from Italy on February 21. He denied any fever, rhinorrhea, nasal congestion, cough, sore throat, shortness of breath, or malaise. Oropharyngeal and nasopharyngeal swabs were positive for SARS-CoV-2 by real-time reverse transcription polymerase chain reaction (RT-PCR) assay. On admission he was found to have a fever of 38.9°C, with a blood pressure 142/94 mm/Hg, pulse 78 beats per minute, respiratory rate 20 breaths per minute, and oxygen saturation 98% when breathing ambient air. Both lungs were clear on auscultation and the remainder of the physical examination was unremarkable. Laboratory results revealed thrombocytopenia, with a lymphocyte count of 0.90 (1.50 -4.00) cells/µL. His inflammatory markers were elevated, with C-reactive protein (CRP) of 28.1 (0-5) mg/L. Liver function and renal function were within the normal range. The respiratory virus panel (BioFire, FilmArray, bioMérieux, Salt Lake City, UT) was negative for influenza A and B as well as Middle East Respiratory Syndrome (MERS CoV). A chest X-ray done on admission revealed infrahilar infiltrates. The patient was diagnosed with COVID-19. Supportive care and therapy were initiated with darunavir 600 mg orally twice daily, ritonavir 100 mg orally twice daily, and J o u r n a l P r e -p r o o f hydroxychloroquine 400 mg orally once daily, with close monitoring of his clinical status. His QTc interval at baseline and on follow-up were normal. On March 6 (hospital day 6), his chest X-ray showed worsening infiltrates and he had persistent fever and worsening lymphopenia. Favipiravir was added to his regimen at a loading dose of 1,600 mg orally every 12 hours, followed by 600 mg orally every 8 hours, and hydroxychloroquine was discontinued. He continued to have daily fever (maximum temperature 39.8°C), and on A 37-year-old male presented with fever and dry cough and was admitted to our institution on March 19, 2020. The patient was known to have been exposed to a SARS-CoV-2 positive patient and oropharyngeal and nasopharyngeal swabs were positive for SARS-CoV-2. The patient had no significant past medical history and reported no other symptoms. Physical examination showed a body temperature of 39.2°C, blood pressure 135/64 mmHg, pulse 102 beats per minute, respiratory rate 20 breaths per minute, and oxygen saturation was 100% when breathing ambient air. Laboratory results on admission showed a complete blood count that was within normal limits and mildly elevated CRP 15 mg/L (Table 1) . A chest Xray on admission was unremarkable. He received therapy for COVID-19 with hydroxychloroquine 400 mg orally once daily and lopinavir/ritonavir 400 mg/100 mg orally twice daily for 10 days. The patient continued to have fever; therefore, sputum culture and gram stain were obtained and the patient was initiated on empirical antibacterial therapy with azithromycin. A CT scan done on March 22 (hospital day 4) showed bilateral patchy ground glass infiltrates in the upper lobes and lower lobes ( Figure 1B) . A larger area of infiltrate was present in the right lower lobe in the posterobasal segment, which had an air bronchogram in it. He continued to have persistent fever, along with elevated ferritin levels of 908 µg/L and favipiravir was added to his regimen at a loading dose of 1,600 mg orally every 12 hours followed by 600 mg orally every 8 hours. On March 25 (hospital day 7) the patient's clinical condition worsened, with his oxygen saturation decreasing to 93% when breathing ambient air and he was initiated on oxygen at 2 L/min. His CRP increased to 55 mg/L and ferritin J o u r n a l P r e -p r o o f continued to increase to 1,847 µg/L (Table 1) . His lymphocyte count decreased to 0.56 cells/µL. Peginterferon alfa 2a was initiated on that day at 180 µg per week for two doses administered subcutaneously. He became afebrile the next day after administration of the first dose of peginterferon. He was also started empirically on cefepime for possible hospitalacquired pneumonia, which was later de-escalated to amoxicillin-clavulanate when sputum cultures showed growth of normal oral flora. Over the course of the next few days, his oxygen requirements decreased and was able to maintain an oxygen saturation of 98 -100% when breathing ambient air. His lymphocyte count continued to increase and inflammatory markers were improving and on April 3 (hospital day 16), his lymphocyte count increased to 1.48 cells/µL and his CRP normalized at 4.5 mg/L. A chest X-ray showed interval improvement, without complete resolution of bilateral lower lung airspace disease. The patient continued to improve and was discharged from the hospital on April 9 (hospital day 22). A 61-year-old year old male with a known past medical history of type 2 diabetes mellitus, Patients with COVID-19 as reported by Huang et al., typically present with mild symptoms including fever, myalgia or fatigue, and dry cough, with the majority having a favorable outcome [3] . A subset of patients may progress within a week of the onset of their symptoms to have dyspnea and hypoxemia, which may rapidly progress to ARDS, or end-organ failure [3] . The 3 patients described here had features that suggested clinical deterioration and possible clinical progression to ARDS, including high fever, elevated inflammatory markers, and elevated coagulation markers [5] . Additionally, CT findings in our patients closely resembled those reported in the literature whereby involvement was bilateral, with lesions evident in the lower lobes and combination of ground-glass opacities together with consolidation, which is observed as the disease progresses [6] . It has been suggested that COVID-19 presents in three stages: (1) an initial asymptomatic incubation period and a non-severe symptomatic phase; (2) a severe respiratory symptomatic phase (marked by high viral loads) in a small subset of patients; and (3) a later phase of the disease marked by cytokine storm and severe lung inflammation [7] . Given that our patients presented with features showing progression into the later phases of the disease it was prudent to initiate therapy to enhance the immune response at this critical juncture to prevent clinical deterioration into the fatal phase of the disease. Immunomodulatory therapy including interferons have been investigated in the management of coronavirus infections including MERS-CoV and SARS [8] . Type 1 interferon (IFN-1) is among the first cytokines produced during a viral infection and is involved in inflammation, signaling and immunomodulation [9] . It interferes with viral replication and plays a major role in antiviral immunity [9] . Interferons have been extensively studied for their activity J o u r n a l P r e -p r o o f against coronavirus in cell culture, animal models, and clinical studies [9] . While the Type I interferons (alpha and beta) are the most studied, there have been several studies of the Type II (gamma) and III (lambda) interferons [10, 11] . Interferon beta was found to be the most potent interferon subtype in various in vitro studies conducted in SARS-CoV and MERS-CoV [10, 12, 13] . Interferon alfa was investigated in one single arm study with corticosteroids and one openlabel randomized controlled trial with corticosteroids, showing variable outcomes in SARS-CoV [14, 15] . Both interferon alfa and interferon beta with ribavirin were studied in MERS-CoV in observational studies [16, 17, 18] . Two of the studies revealed no difference in treatment outcomes, and a third trial showed a reduction in mortality with the use of interferon beta. However, the observational nature of these trials makes it difficult to draw conclusions on the true efficacy of therapy with interferon [16, 17, 18] . Most recently a pre-print was published on a retrospective study investigating interferon alfa-2b in SARS-CoV-2 in its nebulized form in 77 patients. The trial compared the outcomes of patients who received nebulized interferon alfa-2b or umifenovir monotherapy, versus combination of interferon alfa-2b with umifenovir. The study investigators showed that patients who received interferon therapy experienced more rapid viral clearance compared to those treated with umifenovir alone. The retrospective design of this study in addition to an imbalance in patient demographics at baseline (patients on umifenovir monotherapy were older, had more co-morbidities and presented for admission later in course of their disease) makes it difficult to extrapolate data to a broader patient population. Despite these limitations, this study presents some evidence of the role of interferon in the management of COVID-19 that could be corroborated in future clinical trials [19] . The most recent edition of the Chinese guidelines for management of COVID-19 continue to recommend interferon alfa by nebulization [20] . Although the nebulized formulation would theoretically be more tolerated by minimizing systemic side effects and ensuring adequate concentrations in the respiratory tract, we did not observe any side effects in our patients with the subcutaneous administration. This could be due to the fact that they only only received 1 or 2 doses, which may not have been sufficient to elicit the toxic side effects usually observed with prolonged pegylated interferon alfa 2a therapy (including hepatoxicity, bone marrow suppression and neuropsychiatric side effects). Our report has a few limitations. First, this is a small case series that included no controls. In this preliminary uncontrolled case series of 3 severely ill patients with COVID-19, administration of pegylated interferon was followed by clear improvement in the patients' clinical status within 24-36 hours of administration of the drug. The limited sample size and J o u r n a l P r e -p r o o f study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in a controlled clinical trial. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. World Health Organization Clinical characteristics of coronavirus disease 2019 in China Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China Emerging 2019 novel coronavirus (2019-nCoV) pneumonia Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review COVID-19 and emerging viral infections: The case for interferon lambda Interferon, ribavirin, 6-azauridine, and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome Ribavirin and interferon therapy for critically ill patients with Middle East respiratory syndrome: A multicenter observational study IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study Interferon-a2b treatment for COVID-19. medRxiv, 2020 National Health Commission & State Administration of Traditional Chinese Medicine. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) We thank all physicians, pharmacists, nurses and all other clinical caregivers who provided care for these patients and who are providing continuous care to other patients in the UAE.